Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

ditions, including if they have or have had liver problems, diabetes or high blood sugar, high cholesterol levels, infections, hepatitis B or other medical conditions.

Patients should tell their healthcare provider if they are scheduled to receive any vaccinations. Patients should not receive a live vaccine or be around people who have recently received a live vaccine during treatment with Afinitor.

It is not known if Afinitor will harm an unborn baby. Women should use effective birth control while using Afinitor and for eight weeks after stopping treatment.

Common side effects of Afinitor in patients with advanced pancreatic neuroendocrine tumors include mouth ulcers, rash, diarrhea, swelling of arms, hands, feet, ankles, face or other parts of the body, abdominal pain, nausea, fever and headache. Common side effects of Afinitor in patients with advanced kidney cancer include mouth ulcers, infections, feeling weak or tired, cough and diarrhea. Common side effects of Afinitor in patients with SEGA include mouth ulcers, infections of the respiratory tract, sinuses and ears and fever.

Please see full Prescribing Information for Afinitor.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "will," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for everolimus or regarding potential future revenues from everolimus. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with everolimus to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that everolimus will be submitted or approved for any additional indication
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Research and Markets has announced ... Markets" report to their offering. ... - including products to treat cancer, diabetes, HIV/AIDS and ... the final stages of clinical drug testing for new ... production capital to upscale while anticipating FDA or EMA ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
(Date:9/23/2014)... Sept. 23, 2014   COTA, Inc. today ... $7 million Series A funding round led by Horizon ... is the first big data platform designed by practicing ... analysis for cancer care in support of healthcare,s new ... to expand development of the COTA platform, hire biostatisticians, ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... monitoring board (DSMB) has,recommended continuation of the company,s ... brief intravenous infusion of Viprinex(TM) (ancrod),started within 6 ... 3,months. This is the fifth DSMB meeting for ...
... Genmab has,announced that HuMax-EGFr (zalutumumab) inhibits epidermal ... factor receptor (EGFr),molecules into a very compact, ... central to its role in signaling, and ... of cancer cell growth., Genmab A/S ...
Cached Medicine Technology:Fifth DSMB Meeting Supports Neurobiological Technologies' Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod) 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 2Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... Savannah, GA (PRWEB) September 23, 2014 ... local community through philanthropic support. Most recently, the gym ... through their Ageless Fitness program. Throughout the year, World ... for many other charitable causes. , Over the summer, ... Meals on Wheels. Through their Ageless Fitness program, participants ...
(Date:9/23/2014)... Dr. Connie Casad has announced that she ... office space at 12200 Park Central Drive, Suite 200, Dallas, ... be Park Cities Aesthetics, Optimal Health and Wellness, her gynecology ... move, Dr. Casad said, “The patients’ comfort and satisfaction are ... want them to always feel like their needs are valued ...
(Date:9/23/2014)... News) -- Both drinking and getting drunk at an ... by high school students, a new study suggests. ... students who drink, could help expand alcohol-prevention efforts aimed ... stop them from becoming binge drinkers, the researchers suggested. ... alcohol use and progression to first heavy use as ...
(Date:9/23/2014)... Grinnell Mutual seeks submissions from the ... Midwest. Working Together Making It Better will provide ... projects positively impacting their communities. , “So many ... communities a better places,” said Grinnell Mutual ... Baker. “Their leadership—as coaches, as volunteers, as mentors—help ...
Breaking Medicine News(10 mins):Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3Health News:Grinnell Mutual Invites Submissions for Innovative, Collaborative Local Projects in Its Second Annual Working Together Making It Better Promotion 2
... Number of AIDS-Related Deaths Continued to Decline, WASHINGTON, ... who were HIV infected or had confirmed AIDS on ... the end of 2004, the Justice,Department,s Bureau of Justice ... consecutive year the number has fallen. In 1999 there,were ...
... SAN DIEGO, Sept. 27 NuVasive, Inc. (Nasdaq:,NUVA), a ... surgical treatments for the spine, announced today,details relating to ... on Wednesday, October 24, 2007, after the close of ... Wednesday, October 24, 2007 at,5:00 p.m. ET / 4:00 ...
... in preparation for partnering, CARLSBAD, Calif., Sept. ... today announced its purchase of all,of the equity ... $120,million. Prompting this transaction, on September 13, 2007, ... a,Johnson & Johnson company, to discover, develop and ...
... Calif., Sept. 27 The following was ... A new "study" released Wednesday by Death ... group) board member Margaret Peggy Battin,attempts to ... "disproportionately",impacted by assisted suicide legalization in Oregon ...
... For Humanity Continued By Binson,s Home ... Family Presented With New Home Saturday, September 22nd On Detroit,s East ... ... able to,enjoy a fresh start with a new home thanks in part to the ...
... Care,Management Association (PCMA) issued the following response to ... "PCMA member companies have routinely paid clean ... doing so. Before rushing to judgment,on the issue ... conduct an,independent study to explore this issue generally ...
Cached Medicine News:Health News:HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005 2Health News:HIV/AIDS Cases Among State and Federal Prison Inmates Fell for the Sixth Straight Year During 2005 3Health News:NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results 2Health News:NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results 3Health News:Isis Acquires Symphony GenIsis 2Health News:Isis Acquires Symphony GenIsis 3Health News:Californians Against Assisted Suicide: Assisted Suicide 'Study' From Biased Author is Questionable at Best 2Health News:Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home 2
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Cannula: .90mm x 28mm (20 G x 1 1/8 in) Handle: 9.3cm (3 5/8 in) long, Flute, .90 x 28mm, vacuum handle [Charles]...
...
Medicine Products: